Mankind Pharma profit and loss

Latest FY26

Revenue: ₹14,278cr+17.0% on FY25
EBITDA: ₹3,617cr+19.9% on FY25
Net profit: ₹1,938cr−3.6% on FY25
EPS: ₹46.35−5.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	15,379	14,278	12,207	10,335	8,749	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	327	359	537	281	129
	15,705	14,636	12,744	10,616	8,878
	2,468	2,288	2,016	1,854	1,814
	2,005	1,728	1,656	1,410	809
	−234	36.1	−183	−53.7	291
	3,438	3,184	2,692	2,275	1,918
	514	639	429	33.5	44.5
	907	886	621	398	326
	3,625	3,424	3,008	2,315	2,017
	12,723	12,186	10,240	8,231	7,219
	4,077	3,617	3,018	2,535	1,901
	3,170	2,731	2,397	2,137	1,575
Profit
	2,983	2,451	2,504	2,384	1,659
	−130	−130	0.0	0.0	0.0
	2,853	2,321	2,504	2,384	1,659
	739	583	596	493	328
	−136	−188	−86.3	−35.0	34.0
	603	395	510	458	362
	13.8	11.7	12.2	15.2	12.4
	2,264	1,938	2,011	1,942	1,310
	2,250	1,926	1,994	1,927	1,297
	0.0	0.0	4.5	0.0	0.0
	13.7	57.0	−8.3	−8.0	−1.9
	2,277	1,995	2,003	1,934	1,308
	—	1,913	1,986	1,913	1,282
	—	25.2	20.2	28.9	27.8
Per share
	₹54.33	₹46.35	₹49.28	₹47.75	₹32.00
	₹54.24	₹46.28	₹49.19	₹47.68	₹32.00
Continuing & discontinued operations
	0.0	0.0	8.5	0.0	0.0
	0.0	0.0	3.9	0.0	0.0
Other comprehensive income — detail
	13.7	57.0	−8.3	—	—
	17.6	31.9	−5.6	−9.7	−7.4
	2.8	6.2	−3.5	—	—
	—	—	—	−3.6	−2.6
	−1.1	31.3	−6.2	−2.0	2.9
	—	1,970	1,983	1,905	1,280
	—	25.6	20.0	29.1	27.9
Per share — as-filed variants
	₹54.33	₹46.35	₹49.17	₹47.75	₹32.00
	₹54.24	₹46.28	₹49.08	₹47.68	₹32.00
	₹0.00	₹0.00	₹0.11	₹0.00	₹0.00
	₹0.00	₹0.00	₹0.11	₹0.00	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	11,140	10,226	8,718	7,125	5,836
	72.4%	71.6%	71.4%	68.9%	66.7%
Adjusted (ex-exceptional items) — derived
	2,983	2,451	2,504	2,384	1,659
	−130	−130	0.0	0.0	0.0
	2,366	2,046	2,011	1,942	1,310
	₹56.79	₹48.93	₹49.28	₹47.75	₹32.00

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,490.00

Mankind Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹1.03L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	8,749.4	10,334.8	12,207.4	14,277.6	15,378.6
Other Income	128.6	280.9	536.8	358.8	326.9
Total Income	8,878.0	10,615.6	12,744.2	14,636.4	15,705.5
Expenses
+ Cost of Materials Consumed	1,813.7	1,853.5	2,016.4	2,288.0	2,467.7
+ Purchases of Stock-in-Trade	809.2	1,409.9	1,655.7	1,728.0	2,005.0
+ Changes in Inventories	290.7	-53.7	-183.0	36.1	-233.8
+ Employee Benefit Expense	1,918.5	2,274.7	2,692.4	3,183.9	3,437.8
+ Finance Costs	44.5	33.5	429.4	639.3	513.9
+ Depreciation & Amortisation	325.9	398.3	621.2	886.2	907.1
+ Other Expenses	2,016.7	2,315.3	3,008.1	3,424.2	3,625.2
Total Expenses	7,219.2	8,231.5	10,240.1	12,185.7	12,722.8
EBITDA	1,900.6	2,535.1	3,017.9	3,617.4	4,076.8
EBIT	1,574.7	2,136.8	2,396.7	2,731.2	3,169.6
Profit
PBT before Exceptional Items	1,658.8	2,384.1	2,504.1	2,450.7	2,982.7
+ Exceptional Items	0.0	0.0	0.0	-129.8	-129.8
Pretax Income	1,658.8	2,384.1	2,504.1	2,321.0	2,852.9
+ Current Tax	327.6	492.6	596.0	582.9	739.3
+ Deferred Tax	34.0	-35.0	-86.3	-188.3	-136.1
Tax Expense	361.6	457.6	509.7	394.6	603.2
+ Share of Associates & JVs	12.4	15.2	12.2	11.7	13.8
Net Income	1,309.7	1,941.8	2,011.1	1,938.1	2,263.5
+ Net Income — Continuing Ops	1,297.3	1,926.6	1,994.4	1,926.4	2,249.7
+ Net Income — Discontinued Ops	0.0	0.0	4.5	0.0	0.0
+ Other Comprehensive Income	-1.9	-8.0	-8.3	57.0	13.7
Total Comprehensive Income	1,307.8	1,933.8	2,002.8	1,995.1	2,277.2
Net Income to Common	1,281.9	1,912.9	1,986.4	1,912.9	—
Minority Interest	27.8	28.9	20.2	25.2	—
Per Share
Basic EPS	32.00	47.75	49.28	46.35	54.33
Diluted EPS	32.00	47.68	49.19	46.28	54.24
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	8.5	0.0	0.0
+ Tax — Discontinued Operations	0.0	0.0	3.9	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-8.3	57.0	13.7
+ Items NOT to be Reclassified to P&L	-7.4	-9.7	-5.6	31.9	17.6
+ Tax on Items NOT to be Reclassified	—	—	-3.5	6.2	2.8
+ Tax on Items NOT to be Reclassified — alt tag	-2.6	-3.6	—	—	—
+ Items to be Reclassified to P&L	2.9	-2.0	-6.2	31.3	-1.1
Comprehensive Income — Owners of Parent	1,279.9	1,904.7	1,982.8	1,969.5	—
Comprehensive Income — Non-controlling Interests	27.9	29.1	20.0	25.6	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	32.00	47.75	49.17	46.35	54.33
Diluted EPS — Continuing Operations	32.00	47.68	49.08	46.28	54.24
Basic EPS — Discontinued Operations	0.00	0.00	0.11	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	0.00	0.11	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	5,835.8	7,125.1	8,718.4	10,225.5	11,139.7
Gross Margin %	66.70	68.94	71.42	71.62	72.44
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,658.8	2,384.1	2,504.1	2,450.7	2,982.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-129.8	-129.8
Net Income Adj (tax-effected)	1,309.7	1,941.8	2,011.1	2,045.8	2,365.8
EPS Adj	32.00	47.75	49.28	48.93	56.79
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Filed Debt Equity	—	—	0.59	0.39	—
Filed Dscr	—	—	0.60	0.47	—
Filed Iscr	—	—	130.55	4.09	—
Paid Up Equity Capital	40.1	40.1	41.3	41.3	41.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.